With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
The current price of Novo Nordisk A/S in the market is ₺2.173,41, with a 24-hour trading volume of ₺7,44B. The asset's market cap is ₺9,63T, after moving 7.11% in the last day.
Tokenized Novo Nordisk A/S is trading at ₺2.223,8, with a tokenized market cap of ₺179,63M and a 24-hour trading volume of ₺49,95M. The tokenized asset has moved 7.28% in the past 24 hours.